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Altered glycosylation patterns of plasma proteins are associated
with autoimmune disorders and pathogenesis of various cancers.
Elucidating glycoprotein microheterogeneity and relating subtle
changes in the glycan structural repertoire to changes in protein–
protein, or protein–small molecule interactions, remains a significant
challenge in glycobiology. Here, we apply mass spectrometry-based
approaches to elucidate the global and site-specific microheteroge-
neity of two plasma proteins: α1-acid glycoprotein (AGP) and hap-
toglobin (Hp). We then determine the dissociation constants of the
anticoagulant warfarin to different AGP glycoforms and reveal how
subtle N-glycan differences, namely, increased antennae branching
and terminal fucosylation, reduce drug-binding affinity. Conversely,
similar analysis of the haptoglobin–hemoglobin (Hp–Hb) complex
reveals the contrary effects of fucosylation and N-glycan branching
on Hp–Hb interactions. Taken together, our results not only eluci-
date how glycoprotein microheterogeneity regulates protein–drug/
protein interactions but also inform the pharmacokinetics of plasma
proteins, many of which are drug targets, and whose glycosylation
status changes in various disease states.
glycoprotein | mass spectrometry | protein interactions
Glycosylation is one of the most common and complex post-translation modifications that influences the structural and
functional properties of proteins (1–3). N-linked glycans are co-
valently linked to asparagine (Asn) residues during protein trans-
lation. They are biosynthesized and processed by a series of
glycosyltransferases and glycohydrolases in a non–template-directed
manner, giving rise to heterogeneous glycoforms that impact pro-
tein folding, stability, protein–protein interactions, and cell–cell
recognition (2, 3). The subtle variations in glycan structure are
regulated by primary amino acid sequence, as well as quaternary
structure and the repertoire of processing enzymes alongside the
Golgi apparatus transit times in the glycoprotein-producing cells
(4). Changes in glycosylation are associated with many diseases and
play direct roles in pathological processes, including cancer me-
tastasis, diabetes, and inflammation (5, 6). Moreover, the efficacy of
a number of biotherapeutics, such as cytokines, hormones, Fc-
fusion proteins, and monoclonal antibodies, are known to be af-
fected by their glycosylation status (7). It is crucial therefore to
elucidate functional properties of individual glycan structures and
relate site-specific glycosylation to ligand or drug interactions.
Due to the complexity of glycoproteins and the limitations of
existing analytical methodologies, the distribution of glycans on
a protein glycosylation site, commonly known as its micro-
heterogeneity, and their impact on protein–ligand/drug binding is
not fully understood. Current lectin-array and mass spectrometry
(MS)-based glycomics approaches target the collective pool of en-
zymatic or chemically released glycans from all sites simultaneously.
As a result, these approaches do not define the site of specific
glycan structures. Other methods to study glycoprotein interactions,
namely, isothermal titration calorimetry, surface plasmon reso-
nance, and analytical ultracentrifugation, lack detailed affinity in-
formation for individual glycoproteoforms (8). Methods to produce
homogeneous glycoproteins are available, including exoglycosidase
digestion or expression in glycosyltransferase-engineered cell lines,
but these glycoprotein products typically differ from the “wild-type”
form and therefore preclude functional studies of biologically
relevant glycosylation.
The recent emergence of high-resolution native MS represents
a tool for glycobiology capable of measuring both glycan compo-
sition and glycosylation site occupancy of intact glycoproteins (9–
11). Supplemented by established liquid chromatography (LC)-
MS/MS–based glycoproteomics methods, native MS enables a
comprehensive understanding of protein glycosylation and is ca-
pable of revealing over 200 glycoproteoforms on a single glyco-
protein (12). In parallel to these developments in glycobiology,
high-resolution native MS has been developed to measure pro-
tein–drug interactions quantitatively and to analyze variable drug
affinities for different proteoforms (13, 14), but not previously for
glycoproteoforms. Here, we describe the development and appli-
cation of an approach to investigate glycoprotein interactions
between drugs and proteins using two plasma proteins: α1-acid
glycoprotein (AGP) and haptoglobin (Hp). We focus, first, on
elucidating their structural microheterogeneity and, second, on
how this heterogeneity impacts drug or protein binding.
The high-abundance acute-phase plasma protein AGP is a main
carrier of many endogenous hormones, lipids, and exogenous drugs,
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and is proposed to deliver bound drugs to cells by conformational
changes induced by the cell membrane (15). These drug-binding
mechanisms are complicated, however, since AGP carries five
highly sialylated and branched complex type N-glycans (15, 16).
Two N-glycans at Asn38 and Asn75 border the entrance to the
primary drug-binding site of AGP, a hydrophobic cavity about
9–12 Å, revealed by X-ray crystallography of the recombinant
nonglycosylated protein (17, 18). There is evidence for a cor-
relation between aberrant AGP glycosylation and altered drug-
binding capacity, but as yet there is no molecular detail of this
modulation (19–21).
A second high-abundance acute-phase plasma glycoprotein,
Hp, clears free hemoglobin (Hb) from lysed erythrocytes, elimi-
nating Hb-induced oxidative stress and recycling iron in tissues
and the body (22). It consists of two nonglycosylated α-subunits
(Hp α) and two heavily glycosylated β-subunits (Hp β) cross-linked
by disulfide bonds. Hp β-subunits mediate the binding of the Hp–
Hb complex to the scavenger receptor CD163, facilitating the
endocytosis of the complex by macrophages (23). It is reported
that a small fraction of human Hp, which binds weakly to Hb,
exhibits an altered glycosylation pattern (24). How glycoprotein
microheterogeneity of Hp modulates its affinity for Hb through N-
glycosylation, however, is unclear.
Here, we develop and apply high-resolution native MS and LC-
MS–based glycoproteomics methods to first define the global and
site-specific microheterogeneity of AGP and Hp. Using a common
anticoagulant drug (warfarin) that binds to the hydrophobic cavity of
AGP with a dissociation constant of 4 μM (25, 26), we then correlate
changes in drug-binding kinetics to specific glycan structures. We
then contrast and compare these results with a quantitative analysis
of the effects of Hp glycosylation on Hp–Hb interactions.
Results
MS Analysis Reveals the Complex Microheterogeneity of AGP.AGP is
known to have five glycosites occupied by complex type N-glycans
with multiple antennary α1–3-linked fucose and N-acetylneuraminic
acid (Neu5Ac) residues forming sialyl LewisX epitopes on Asn15,
Asn38, Asn54, Asn75, and Asn85 (Fig. 1A) (16, 27, 28). AGP F1
and S variants are the most common proteoforms with 1-aa dif-
ference (F1, Gln-20, and S, Arg-20) (29–31). The native MS
spectrum of sialylated AGP is highly complex due to the varying
degree of sialylation across all sites (SI Appendix, Fig. S1). Im-
portantly, the mass of two fucose residues (292.29 Da) and one
Neu5Ac (291.26 Da) are similar and cannot be resolved on the
intact protein by native MS (32). Therefore, assignment of the
glycan composition of the highly heterogeneous sialylated AGP
is ambiguous in terms of fucosylation and sialylation. We se-
lected asialo-AGP (neuraminidase-treated AGP) for the fol-
lowing experiments to reduce the complexity of the spectrum
and to improve our assignments.
The native mass spectrum of asialo-AGP shows a peak envelope
from m/z 2,900–4,300 with reduced spectral complexity com-
pared with the sialylated form (Fig. 1A). After deconvolution by
UniDec software (33), the base peak (32,213 Da) was assigned as
Hex32HexNAc27Fuc0, which is within 1 Da of the theoretical
glycoprotein mass [AGP F1 variant peptide backbone, 21,539.06;
Hex32HexNAc27Fuc0 residue mass, 10,674.82 Da; Hex for man-
nose (Man) and galactose (Gal); HexNAc forN-acetylglucosamine
(GlcNAc), Fuc for fucose] (Fig. 1B). N-glycosylation is established
as the only posttranslational modification on AGP accounting for
this heterogeneity (15). Two series of peak were identified with a
28-Da mass difference, corresponding to the known AGP F1 and S
variants (Fig. 1B, blue and yellow peaks). The other peaks in the
mass spectrum were assigned to the corresponding glycoproteo-
forms based on mass differences of 146.1430 Da (Fuc1) for fuco-
sylation and 365.3374 Da (Hex1HexNAc1) for N-glycan branching
and elongation (Fig. 1B). We found that N-glycan branching
and fucosylation could account for all observed AGP glycan
heterogeneity and were consistent with the 10 main peak series
with Hex1HexNAc1 differences (marked P0 to P9 in Fig. 1B). Each
peak series contains five glycoproteoforms ranging from unfuco-
sylated to tetrafucosylated (Fuc0 to Fuc4, Fig. 1B). Importantly, the
difference in mass between five fucose residues (730.715 Da) and
Hex2HexNAc2 (730.6748 Da) is 0.0402 Da. Therefore, we cannot
rule out the presence of low-abundance highly fucosylated AGP
carrying five or more fucose residues that overlap with other peaks
in the native mass spectra. However, given this caveat, from the
baseline-resolved peaks and applying a 5-Da mass tolerance, we
were able to identify over 90 glycoproteoforms (Fig. 1B and SI
Appendix, Table S1). We also evaluated the site-specific micro-
heterogeneity of asialo-AGP by glycoproteomics and glycomics (SI
Appendix, Figs. S2 and S3), and revealed that the glycan compo-
sition and relative abundance of N-glycan branching/elongation on
each N-glycosylation site are in agreement with previous reports
(16, 28). Importantly, Neu5Ac residue was not detected by either
glycoproteomics or glycomics analysis, suggesting that the neur-
aminidase reaction went to completion and confirming the native
MS assignment of asialo-AGP (Fig. 1B).
Native MS Analysis Resolves the Microheterogeneity of Hp. The hu-
man plasma Hp has a genetic polymorphism expressed by two
alleles HP1 and HP2, resulting in three major phenotypes: Hp1-1,
Hp2-1, and Hp2-2 (34). Here, we selected the simplest form
Fig. 1. Native MS analysis of asialo-AGP. (A) Native mass spectrum of asialo-
AGP. AGP structure with five highly branched N-glycans at Asn15, Asn38,
Asn54, Asn75, and Asn85 are shown. The monosaccharide residues are labeled
according to the Consortium for Functional Glycomics guidance (blue for
GlcNAc, yellow for Gal, and green for Man). (B) A zero-charged native mass
spectrum of asialo-AGP is constructed using UniDec. Each peak is assigned to
the corresponding glycan composition (SI Appendix, Table S1). Peaks with the
same hexose (Hex) and N-acetylhexosamine (HexNAc) numbers are labeled P0
to P9. The number of fucose residues assigned to each peak (Fuc0 to Fuc4) is
denoted with colored arrows. The presence of an “uncapped” GlcNAc residue
on AGP is denoted with a red asterisk (*). This may arise either from in-
complete processing of AGP, escaping from the N-glycosylation biosynthesis
pathway, or from degradation AGP in vivo and/or in vitro.
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Hp1-1 consisting of two α1 (9.1 kDa) and two glycosylated
β-subunits (40 kDa) for native MS analysis. Each β-subunit has
four highly sialylated complex type N-glycans with antennary α1–3-
linked and/or core α1–6-linked fucose on Asn180, Asn203, Asn207,
and Asn237 (Fig. 2A) (35, 36). The native MS spectrum of Hp
shows a peak envelope from m/z 4,600–6,300 with partially over-
lapping charge states (SI Appendix, Fig. S4). The asialo-Hp native
mass spectrum exhibits significantly reduced complexity with less
overlapping charge states (Fig. 2B). The glycan composition of
the base peak (86,615 Da) was assigned as Hex42HexNAc34Fuc0
within 0.1 Da of the theoretical mass of 86,615.08 Da (Hp protein
backbone, 72,896.47 Da; Hex42HexNAc34Fuc0 residue mass,
13,718.61 Da) (P3 form in Fig. 2B). Other peaks were assigned to
the corresponding glycoproteoforms based on mass differences of
146.1430 Da (Fuc1) for fucosylation and 365.3374 Da (Hex1HexNAc1)
for N-glycan branching and elongation (SI Appendix, Table S2).
Notably, the glycan composition of the P0 form (Hex39HexNAc31)
suggests the presence of one monoantennary and seven biantennary
N-glycans on Hp. We also found the presence of partially glycosy-
lated Hp which has seven N-glycans (Fig. 2B and SI Appendix, Table
S2). The N-glycan occupancy at N237 gives rise to this heteroge-
neity at the glycoprotein level (37). The glycoproteomics analysis
of asialo-Hp revealed biantennary and triantennary N-glycans are
predominantly distributed on all four glycosylation sites (SI Ap-
pendix, Fig. S5). We also detected the presence of monoantennary
N-glycan on Asn237, supporting the native MS assignment of
asialo-Hp (Fig. 2B).
Comparing the results for Hp to those of AGP shows higher
sialylation, and less fucosylation and N-glycan branching on Hp.
Because the labile Neu5Ac residues are not stable in glyco-
proteomics analysis (38) and largely complicate the native mass
spectrum, we selected asialo-Hp and asialo-AGP for the fol-
lowing experiments to reduce the complexity of the spectrum and
to improve the assignment.
N-glycan Branching and Fucosylation Reduce the Affinity of Asialo-
AGP to Warfarin. N-glycans can function to stabilize glycoprotein
structures and also decrease glycoprotein dynamics (39). Due to
their inherent flexibility and heterogeneity, the influence of N-
glycosylation on protein–drug interactions is complex and in most
cases not fully understood. To explore asialo-AGP interactions with
drugs, we selected warfarin, a well-known anticoagulant plasma
protein drug for which in-solution studies have shown stoichio-
metric binding to AGP (25). First, we examined asialo-AGP with an
excess of warfarin, ∼1 μM asialo-AGP and 50 μM warfarin in
200 mM ammonium acetate and 1% dimethyl sulfoxide (DMSO).
Noncovalent interactions between asialo-AGP and warfarin were
maintained in the gas phase with warfarin binding to each glyco-
proteoform (+308.33 Da) clearly observed (Fig. 3A). Charge state
reduction was also apparent in the mass spectrum due to the effect
of low levels of DMSO (40). Interestingly, we found that asialo-
AGP bound warfarin with 1:1 stoichiometry without any non-
specific binding detected in a 50-fold excess of warfarin (Fig. 3A).
Next, we measured the affinity of asialo-AGP binding to war-
farin through titration of increasing concentrations of the drug in
200 mM ammonium acetate and 1% DMSO. Peaks assigned to
unfucosylated and monofucosylated glycoproteoforms bound to
warfarin were clearly resolved with high signal-to-noise ratios. The
relative abundance of nonfucosylated and monofucosylated peaks
as a function of drug concentration were extracted and normalized
by UniDec software (33) and fit to a single-site specific binding
model for dissociation constant (Kd) calculations. The Kd of war-
farin binding to 16 unfucosylated and monofucosylated glyco-
proteoforms (identified as P1 to P8) ranged from 200 to 500 nM
(Fig. 3B) and are in broad agreement with the average value
obtained via in-solution measurements (Kd of 4 μM) (25). Impor-
tantly, we found that fucosylation significantly reduces the affinity
of asialo-AGP to warfarin. Similarly, N-glycan branching/elonga-
tion also decreases asialo-AGP binding to warfarin (Fig. 3C).
It is notable that fucosylation has a greater influence on inhib-
iting AGP binding to warfarin than N-glycan branching/elongation,
despite the fact that addition of a single fucose residue (146 Da) is
less than the addition of Hex1HexNAc1 unit (365 Da). This implies
that, for inhibition of warfarin binding to asialo-AGP, the size of
the additional monosaccharide residue is not as important as the
steric hindrance of the species as a result of the position of the
linkage of the monosaccharide residue. It is likely that fucosylation
and N-glycan branching/elongation introduces steric hindrance to
warfarin by preventing access to the drug-binding cavity (Fig. 3D).
Previously, an inverse relationship between AGP drug-binding
capacity and GlcNAc/Man ratio has been reported (20, 21). Our
results directly show that N-glycan branching (Hex1HexNAc1) and
fucosylation (Fuc1) attenuate the AGP affinity to the drug. We
rationalize this finding by providing Kd measurements for individ-
ual drug-binding events for defined glycoproteoforms. In this way,
we have been able to assign functional properties to discrete
complex N-glycans on the surface of AGP (see Fig. 5).
Fucosylation and N-glycan Branching Regulates Hp Interactions to Hb.
To explore the impact of glycosylation on protein–protein in-
teraction, we quantitatively studied the high-affinity interaction
Fig. 2. Resolving the microheterogeneity of asialo-Hp. (A) Native mass
spectrum of asialo-Hp. Hp structure with four biantennary N-glycans at
Asn180, Asn203, Asn207, and Asn237 at each Hp β-subunit is shown. (B) A
zero-charged native mass spectrum of asialo-Hp. Each peak is assigned to the
corresponding glycan composition (SI Appendix, Table S2). Peaks with the
same Hex and HexNAc numbers are labeled P0 to P9. The number of fucose
residues assigned to each peak (Fuc0 to Fuc4) is denoted with colored arrows.













of human asialo-Hp and the human Hb heterodimer (Fig. 4A)
(41, 42). First, we analyzed asialo-Hp by native MS and calculated
the relative abundances of unfucosylated and monofucosylated
peak series of fully glycosylated Hp (eight N-glycans) with high
signal-to-noise ratios (P1 to P7, Fig. 4B). Then we analyzed the
Hp–Hb complex by native MS, which is formed from two Hb holo-
heterodimers (theoretical mass, 32,226.56 Da) binding to one Hp
heterotetramer (Fig. 4C and SI Appendix, Fig. S6). To minimize the
gas-phase unfolding of the Hp–Hb complex, we applied minimal
source energy (50 V) to desolvate the complex and to resolve
unfucosylated, monofucosylated, and fully glycosylated Hp–Hb
complexes (P1 to P7, Fig. 4C). We quantified the relative abun-
dances of unfucosylated and monofucosylated peak series and
compared their abundances to the corresponding glycoproteoforms
in Hp alone (Fig. 4D). Interestingly, fucosylation significantly
stabilizes the Hp–Hb complex. By contrast, N-glycan branching
reduces the affinity of Hp for Hb.
These results imply that the fucose residue on Hp interacts with
Hb to stabilize the Hp–Hb complex and/or alter the orientation of
N-glycan antennae to rectify the steric hindrance of the branched
N-glycans. Notably, monofucosylation on Hp can rescue the nega-
tive effects of N-glycan branching on the Hp–Hb interaction (P1
unfucosylated and P6 monofucosylated; Fig. 4D). Multifucosylation
on Hp largely increases its affinity for Hb (SI Appendix, Fig. S7).
We also captured dissociated Hp–Hb complex, formed by loss of
one holo-Hb β-subunit in the gas phase (Fig. 4E and SI Appendix,
Fig. S8). This observation suggests a weaker interaction between
βHb–Hp than αHb–Hp in agreement with the fact that more
residues are involved in forming αHb–Hp intermolecular inter-
actions (43). The previous Hp–Hb structural data revealed only
the innermost GlcNAc and core fucose residue orientations (42,
43). The highly flexible N-glycan at Asn180 and Asn203 that are
close to the Hp–Hb interface, however, may interact with Hb α
(αHb)- and/or the β (βHb)-subunit (Fig. 4A). Taken together, our
results provide a quantitative assessment of the Hb binding events
to individual Hp glycoproteoforms and reveal the stabilizing and
destabilizing effects on the Hp–Hb complex of N-glycan fucosy-
lation and branching, respectively (Fig. 5).
Discussion
Glycoprotein microheterogeneity arises from the glycan biosyn-
thesis pathway and controls glycoprotein structure and function.
Fig. 3. Native MS analysis of asialo-AGP and warfarin binding. (A) Native
mass spectra of asialo-AGP in 1% DMSO and asialo-AGP with 50 μMwarfarin
in 1% DMSO. Warfarin binding to asialo-AGP results in a mass shift of 308.33
Da. Unfucosylated P3F0/P4F0 and monofucosylated P3F1/P4F1 are labeled as
blue and red peaks, respectively. Warfarin-bound asialo-AGP peaks do not
overlap with apo-asialo-AGP peaks. (B) Plots of the warfarin concentration
to the relative abundances of warfarin-bound unfucosylated (P1F0 to P8F0)
and monofucosylated (P1F1 to P8F1) glycoproteoforms. The abundance of
each peak was normalized to the total abundance of P4F0 form (P4F0 un-
bound and bound peaks). Dissociation constants for each glycoproteoform
were calculated by a one-site specific binding model. Error bars represent
the SE of three replicate experiments. (C) Bar graph of dissociation constants
of unfucosylated (P1 to P8) and monofucosylated (P1 to P8) glycoproteo-
forms show that fucosylation and N-glycan branching elevate dissociation
constant of asialo-AGP to warfarin. (D) AGP structure with warfarin docking
to the hydrophobic cavity. N-glycans on Asn38 and Asn75 are close to the
hydrophobic cavity for drug binding.
Fig. 4. Native MS analysis of asialo-Hp and Hb interactions. (A) Hp–Hb
complex structure. The N-glycans on Asn180 and Asn203 are proximal to the
Hp–Hb interaction interface. Native mass spectra of asialo-Hp and asialo-Hp–
Hb complex (SI Appendix, Fig. S6) are deconvoluted to zero-charged spectra
(B and C) using UniDec. The unfucosylated (blue) and monofucosylated (red)
peak series of fully glycosylated Hp and the corresponding peak series of
Hp–Hb complex with the same glycan compositions are assigned and labeled
as P1 to P7. Their relative abundances are extracted and normalized. The
ratios of their relative abundances are plotted as bar graph (D). Error bars
represent the SE of three replicate experiments. (E) The spectra of gas-phase
dissociated Hp–Hb complexes from which one βHb has been removed.
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Here, we developed high-resolution native MS-based approaches
to qualitatively and quantitatively analyze glycoprotein structural
microheterogeneity and to define specific functional roles to gly-
cans in modulating drug and protein binding. We demonstrated
the global and site-specific microheterogeneity of AGP and Hp.
Taking advantage of high-resolution native MS, we identified drug
binding to defined asialo-AGP glycoforms and quantified the ef-
fects of N-glycan branching and fucosylation on the kinetics of
warfarin binding to AGP. We further quantitatively analyzed Hp–
Hb complexes and unveiled antagonistic functions of N-glycan
branching and fucosylation on Hp–Hb complex stability.
The classic approaches to study glycoprotein–protein interactions
are usually based on perturbation of the interaction by removing a
target glycan determinant completely, such as glycosyltransferase
engineering for N-glycan branching (44) or exoglycosidase digestion
for fucosylation (45). However, such perturbations do not address
the complexities of the interplay between multiple and heteroge-
neous occupied N-glycosylation sites. For example, the multiplicity
of branched N-glycan gradationally determines the interaction of
cell surface receptor kinases with the galectin lattice (46). Here, we
demonstrated that N-glycan branching attenuates AGP-warfarin
and Hp–Hb interactions in a stepwise manner. Furthermore, our
native MS studies of glycoprotein–drug/protein interactions enable
us to resolve a protein complex glycoproteoform at the resolution
of single monosaccharide residues, and thus assess the subtle effects
of glycan fucosylation on protein–drug/protein interactions. Sialy-
lation also plays important roles in regulating protein–protein/
ligand interactions (5), and it is feasible that negatively charged
terminal sialic acids may introduce extra steric hindrance or inter-
act with the protein backbone, changing glycan orientations in
glycoprotein-protein interactions. Although beyond the scope of
this study, which focused on asialo-glycoproteins, additional frac-
tionation will be needed to reduce further the complexity of pro-
tein glycosylation for future studies by native MS.
From the X-ray crystal structure of recombinant AGP, in which
all glycans were removed, it is evident that the N-glycans at Asn-38
and -75 are close to the drug-binding cavity and variable N-
glycosylation, especially fucosylation, may modulate access of the
cavity to warfarin (17). A previous molecular-dynamics study of
AGP revealed that glycosylation expands the volume of the hy-
drophobic cavity for drug binding (47). Although other glycosyla-
tion sites are far from the hydrophobic cavity, the occurrence of
distal antennary fucosylation and N-glycan branching/elongation
may induce conformational changes to the AGP protein backbone,
contributing to a weaker protein–drug interaction. Circulating AGP
is a main drug carrier in the blood and its concentration influences
both pharmacokinetics and pharmacodynamics of drug interactions
(26). Based on our findings, warfarin binding to AGP is driven by
antennary fucosylation and is a crucial consideration for dosage,
especially among patients with different secretor and blood group
status who have variable degrees of protein fucosylation (48).
Our analysis of the Hp–Hb complex shows N-glycosylation can
fine-tune Hp and Hb interactions, even the tight Hp–Hb binding
that is widely described as “irreversible,” involving over 30 van
der Waals and 10 electrostatic interactions (42). For other gly-
coprotein–protein complexes, N-glycans may have greater effects
on their interactions. Fucosylation and N-glycan branching on
Hp are both reported to be elevated in various diseases, such as
pancreatic (49), hepatic (36), and prostate cancers (50). Based
on our results, the Hp glycoproteoforms with higher levels of
fucosylation and lower N-glycan branching have greater affinity
for Hb. Abnormal Hp in patients therefore may capture the free
Hb in blood, delivering it to macrophages more efficiently than
normal Hp glycoproteoforms. The N-glycan at Asn-237 is in
close proximity to the CD163 binding domain (42). Moreover, N-
glycosylations are associated with Hp–Hb complex binding to
galectin-1 controlling different endocytic pathways in macro-
phages (51). Further investigation of fucosylation and N-glycan
branching effects on Hp–Hb complex binding to CD163 and
galectins may be relevant to understanding both the Hb clear-
ance pathway and disease-specific macrophage activation.
As described above, protein fucosylation is globally regulated
and hyperfucosylated glycans on Hp and AGP are elevated in
hepatocellular carcinoma (49, 52). Therefore, probing hyper-
fucosylation on Hp/AGP can provide better clues for identifying
and monitoring changes in glycans associated with diseases. More
generally, glycoproteins have been widely considered as disease
biomarkers; however, the lack of robust and rapid analytical
methods to identify glycoprotein-specific changes has limited their
implementation (53). While our current study addressed pooled
human plasma glycoproteins, we envision that aberrant plasma
glycoprotein microheterogeneity, from plasma of individual pa-
tients, will be addressable with combined affinity-purifications (54).
Native MS has already shown great prominence in probing
protein–drug/ligand binding (55). With this study, we have further
demonstrated high-resolution native MS as a powerful platform
for pharmacokinetics using complex plasma glycoproteins, subject-
ing it to minimal sample preparation, and providing drug–protein-
binding affinities for each glycoproteoform. The platform is
currently unique in that it is able to elucidate the detailed im-
pact of microheterogeneity on drug–protein binding to a gly-
coprotein, uncovering mechanisms by which subtle changes in
N-glycosylation fine-tune the overall protein function. More gen-
erally, this approach could be applied to both soluble and mem-
brane proteins to relate changes in ligand binding affinity directly
to protein modification status.
Methods
Extended experimental and method details can be found in SI Appendix.
Human AGP (product number G9885), human Hp phenotype 1-1 (product
number H0138), and human Hb (product number H7379) were purchased
from Sigma-Aldrich. For native MS analysis, glycoproteins were dissolved in
water, buffer exchanged to 200 mM ammonium acetate (pH 7.6), and an-
alyzed on a modified Q-Exactive mass spectrometer (Thermo Fisher Scien-
tific) (56) and a modified Q-Exactive Plus Orbitrap mass spectrometer (57).
The raw native MS spectra were deconvoluted using UniDec software to
produce zero-charge spectra. Protein and glycan mass calculations were
based on amino acid and monosaccharide average residue masses. AGP–
warfarin and Hp–Hb binding experiments were performed in ammonium
acetate buffer (pH 7.6). Protein structures of AGP [Protein Data Bank (PDB)
ID code 3KQ0] (17) and Hp–Hb complex (PDB ID code 4WJG) (43) were re-
trieved from PDB and processed using University of California, San Francisco
Chimera program (version 1.22) (58).
Fig. 5. The schematic illustration of glycosylation regulation of glycopro-
tein–drug/protein interactions. N-glycan branching and fucosylation may
introduce steric hindrance to the warfarin binding pocket inhibiting AGP–
drug binding. N-glycan branching attenuates Hp–Hb binding affinity. On
the contrary, fucosylation stabilizes the Hp–Hb complex.
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